David Risinger, an analyst from Leerink Partners, has initiated a new Buy rating on ImageneBio (IMA).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Risinger has given his Buy rating due to a combination of factors, primarily focusing on the potential of ImageneBio’s lead asset, IMG-007. This non-depleting anti-OX40 monoclonal antibody is positioned as a potential blockbuster treatment for atopic dermatitis, with early clinical data indicating promising efficacy compared to existing treatments like Dupixent. The recent setbacks faced by competitors in the OX40-OX40L class have created a favorable environment for IMG-007 to stand out with its unique competitive profile.
IMG-007’s “trifecta” competitive profile is highlighted by its safety, efficacy, and convenience. It is designed to be safer than Amgen’s OX40 rocatinlimab, more effective than Sanofi’s OX40L amlitelimab, and offers a longer half-life for less frequent dosing. Additionally, the leadership of CEO Kristin Yarema, with her extensive experience in biotech, is seen as a strategic advantage in optimizing the company’s direction and execution. These factors, along with a robust cash position and a projected launch in 2030, underpin Risinger’s optimistic outlook and Buy rating for ImageneBio.